What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2021-10-14 compared with 2021-07-13 · 91 added, 78 removed, 216 unchanged (44% of the section changed)

Management’s Discussion and Analysis o f Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with (1) the unaudited condensed consolidated financial statements and the related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q and (2) the audited consolidated financial statements and related notes and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended November 30, 2020 included in our Annual Report on Form 10-K filed on February 16, 2021 (2020 Form 10-K).

23 unchanged sentences

Since inception, we have generally incurred significant losses and negative cash flows from operations.

During the six months ended May 31, 2021 and 2020, we incurred net losses of $50.7 million and $4.8 million, respectively.

As of May 31, 2021, we had an accumulated deficit of $154.4 million.

During the nine months ended August 31, 2021 and 2020, we incurred net losses of $79.5 million and $23.3 million, respectively.

As of August 31, 2021, we had an accumulated deficit of $183.2 million.

These losses have resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations.

11 unchanged sentences

and the execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under such arrangements.

As of May 31, 2021, we had $496.5 million in cash, cash equivalents and investments.

As of August 31, 2021, we had $465.4 million in cash, cash equivalents and investments.

In July 2020, we closed our initial public offering and issued 12,550,000 shares of our common stock (including the exercise by the underwriters of their option to purchase an additional 1,550,000 shares of common stock in August 2020) at a price to the public of $19.00 per share for net proceeds of approximately $218.1 million, after deducting underwriting discounts and commissions of $16.7 million and expenses of $3.6 million.

9 unchanged sentences

Collaborations and License Agreements

Gilead Collaboration, Option and License Agreement

In June 2019, we entered into a global strategic collaboration agreement with Gilead, which was amended in August 2019 (the Gilead Agreement), to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases using our DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.

Under the Gilead Agreement, Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commercialization of drug candidates resulting from the collaboration.

We retain the option to co-develop and co-promote, under a profit share structure, up to two drug candidates in the United States under certain conditions.

The collaboration excludes our current internal protein degradation programs for which we retain all rights, and also excludes our future internal programs, provided that we have distinguished future programs as excluded from the scope of the collaboration.

Over time, Gilead may elect to replace the initial drug targets with other drug targets.

For drug targets that are subject to the collaboration, we are obligated to use commercially reasonable efforts to undertake a research program in accordance with a research plan agreed to by the parties and established on a target-by-target basis.

We have primary responsibility under the agreement for performing preclinical research activities (including target validation, drug discovery, identification or synthesis) pursuant to a research plan.

Each party will bear its own costs in the conduct of research activities.

Gilead will be responsible for any development, commercialization and manufacturing activities, unless we exercise our co-development and co-promotion option.

For those programs that we exercise our option to co-develop and co-promote, we and Gilead will split U.S.

development costs as well as U.S.

profits and losses evenly, and we will be eligible to receive royalties on ex-U.S.

net sales and reduced milestone payments.

Upon signing the Gilead Agreement, Gilead paid us an upfront payment of $45.0 million plus $3.0 million in additional fees.

Since the signing of the Gilead Agreement, we have received payments of $13.5 million for research milestones and additional payments, including $2.5 million which was received in the third quarter of 2021.

Additionally, in August 2021, we recognized a research milestone, resulting in a $5.0 million additional payment, which will be received in the fourth quarter of 2021.

As of August 31, 2021, we are eligible to receive up to approximately $2.3 billion in total additional payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones.

In addition, we are eligible to receive tiered royalties from mid-single digit to low tens percentages on annual net sales from any commercial products directed to the optioned collaboration targets, subject to certain reductions and excluding sales in the United States of any products for which we exercise our option to co-develop and co-promote, for which we share profits and losses evenly.

We recognized collaboration revenue from the Gilead Agreement of $6.1 million and $12.5 million during the three and nine months ended August 31, 2021, respectively, and $2.1 million and $6.9 million during the three and nine months ended August 31, 2020, respectively.

As of August 31, 2021, there was $39.1 million of deferred revenue related to payments received by us under the Gilead Agreement.

Sanofi Collaboration and License Agreement

16 unchanged sentences

We are eligible to receive additional payments if Sanofi exercises an option to extend the license term with respect to a particular target.

As of May 31, 2021, we are eligible to receive up to approximately $2.5 billion in total payments based on certain additional fees, payments and the successful completion of certain research development, regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit to low teen percentages on annual net sales of any

commercial products that may result from the collaboration, subject to certain reductions and excluding sales in the United States of any products for which we exercise our option to co-develop and co-promote, for which we share profits and losses evenly.

Since the signing of the Sanofi Agreement, we have received a payment of $1.0 million for research milestones, all of which was received in the third quarter of 2021.

As of August 31, 2021, we are eligible to receive up to approximately $2.5 billion in total payments based on certain additional fees, payments and the successful completion of certain research, development, regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit to low teen percentages on annual net sales of any commercial products that may result from the collaboration, subject to certain reductions and excluding sales in the United States of any products for which we exercise our option to co-develop and co-promote, for which we share profits and losses evenly.

We accounted for the First Sanofi Amendment as if it were part of the existing contract with Sanofi as the remaining goods and services to be provided after the contract modification are not distinct from the goods and services already provided and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification.

1 unchanged sentence

The effect of the revised research period on our measure of progress toward complete satisfaction of the performance obligation was recognized as an adjustment to revenue at the date of the contract modification on a cumulative catch-up basis.

We recognized collaboration revenue from the Sanofi Agreement of $3.3 million and $5.6 million during the three and six months ended May 31, 2021, respectively, and $1.8 million and $2.2 million during the three and six months ended May 31, 2020, respectively.

As of May 31, 2021, there was $65.7 million of deferred revenue related to payments received by us under the Sanofi Agreement.

Gilead Collaboration, Option and License Agreement

We retain the option to co-develop and co-promote, under a profit share structure, up to two drug candidates in the United States under certain conditions.

Over time, Gilead may elect to replace the initial drug targets with other drug targets.

Each party will bear its own costs in the conduct of research activities.

Gilead will be responsible for any development, commercialization and manufacturing activities, unless we exercise our co-development and co-promotion option.

For those programs that we exercise our option to co-develop and co-promote, we and Gilead will split U.S.

development costs as well as U.S.

profits and losses evenly, and we will be eligible to receive royalties on ex-U.S.

net sales and reduced milestone payments.

Upon signing the Gilead Agreement, Gilead paid us an upfront payment of $45.0 million plus $3.0 million in additional fees.

Subsequently, we have received payments of $13.5 million for research milestones and additional payments, including $2.5 million in the second quarter of 2021.

As of May 31, 2021, we are eligible to receive up to approximately $2.3 billion in total additional payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones.

We recognized collaboration revenue from the Gilead Agreement of $3.7 million and $6.5 million during the three and six months ended May 31, 2021, respectively, and $2.4 million and $4.8 million during the three and six months ended May 31, 2020, respectively.

As of May 31, 2021, there was $40.2 million of deferred revenue related to payments received by us under the Gilead Agreement.

We recognized collaboration revenue from the Sanofi Agreement of $4.2 million and $9.8 million during the three and nine months ended August 31, 2021, respectively, and $2.0 million and $4.2 million during the three and nine months ended August 31, 2020, respectively.

As of August 31, 2021, there was $62.5 million of deferred revenue related to payments received by us under the Sanofi Agreement.

Formation of DeCART Therapeutics Inc.

3 unchanged sentences

DeCART granted to its external founders stock options to purchase shares of DeCART’s common stock equal to 14% of the fully diluted capitalization of DeCART.

Following either the third-party funding or the exercise of the stock option grants, DeCART will no longer be a wholly owned subsidiary.

Following either

the third-party funding or the exercise of the stock option grants, DeCART will no longer be a wholly owned subsidiary.

Components of Results of Operations

31 unchanged sentences

We expect our general and administrative expenses to increase substantially for the foreseeable future as we continue to build our infrastructure, increase our headcount and operate as a public company.

This may include expenses related to compliance with the rules and regulations of the SEC and listing standards applicable to companies listed on a national securities exchange, additional insurance, investor relations activities and other administrative and professional services.

We also expect our intellectual property expenses to increase as we

expand our intellectual property portfolio.

This may include expenses related to compliance with the rules and regulations of the

SEC and listing standards applicable to companies listed on a national securities exchange, additional insurance, investor relations activities and other administrative and professional services.

We also expect our intellectual property expenses to increase as we expand our intellectual property portfolio.

Interest and Other Income, Net

6 unchanged sentences

Results of Operations

Comparison of the Three and Six Months Ended May 31, 2021 and 2020

Three Months Ended May 31,

Six Months Ended May 31,

Comparison of the Three and Nine Months Ended August 31, 2021 and 2020

Three Months Ended August 31,

Nine Months Ended August 31,

(in thousands)

8 unchanged sentences

Provision (benefit) for income taxes

Net income (loss)

Collaboration Revenue

Our collaboration revenue for the three and six months ended May 31, 2021 and 2020 is summarized as follows:

Three Months Ended May 31,

Six Months Ended May 31,

Our collaboration revenue for the three and nine months ended August 31, 2021 and 2020 is summarized as follows:

Three Months Ended August 31,

Nine Months Ended August 31,

(in thousands)

Total collaboration revenue

Our collaboration revenue increased by $2.9 million and $5.1 million during the three and six months ended May 31, 2021, respectively, compared to the three and six months ended May 31, 2020.

The increase was due to the continued scale up of internal resources and external spending for our collaborations with Sanofi and Gilead as compared to the prior periods, resulting in a higher percentage of completion in the current periods.

Our collaboration revenue increased by $6.2 million and $11.2 million during the three and nine months ended August 31, 2021, respectively, compared to the three and nine months ended August 31, 2020.

The increase was primarily due to the continued scale up of internal resources and external spending for our collaborations with Sanofi and Gilead as compared to the prior periods, resulting in a higher percentage of completion in the current periods.

The increase was also due to partial revenue recognized during the three and nine months ended August 31, 2021 for the achievement of certain preclinical milestones under our collaborations with Gilead and Sanofi.

Research and Development Expenses

Our research and development expenses for the three and six months ended May 31, 2021 and 2020 are summarized as follows:

Three Months Ended May 31,

Six Months Ended May 31,

Our research and development expenses for the three and nine months ended August 31, 2021 and 2020 are summarized as follows:

Three Months Ended August 31,

Nine Months Ended August 31,

(in thousands)

Compensation and related personnel costs

Stock-based compensation

Supplies and contract research

3 unchanged sentences

Total research and development expenses

Our research and development expenses increased by $11.9 million during the three months ended May 31, 2021, compared to the three months ended May 31, 2020.

The increase was primarily related to an increase of $5.3 million in compensation and related personnel costs attributable to an increase in headcount.

Compensation and related personnel costs includes $1.9 million of non-cash stock-based compensation expense in the three months ended May 31, 2021, compared to $0.2 million in the three months ended May 31, 2020.

There was also an increase of $4.2 million in supplies and contract research attributable to increases in our preclinical development activities and drug discovery research and an increase of $1.1 million in clinical costs due to the start of clinical trial patient enrollment.

Our research and development expenses increased by $21.9 million during the six months ended May 31, 2021, compared to the six months ended May 31, 2020.

Our research and development expenses increased by $12.0 million during the three months ended August 31, 2021, compared to the three months ended August 31, 2020.

The increase was primarily related to an increase of $4.1 million in compensation and related personnel costs attributable to an increase in headcount.

Compensation and related personnel costs includes $3.0 million of non-cash stock-based compensation expense in the six months ended May 31, 2021, compared to $0.3 million in the six months ended May 31, 2020.

There was also an increase of $7.7 million in supplies and contract research attributable to increases in our preclinical development activities and drug discovery research and an increase of $1.8 million in clinical costs due to the start of clinical trial patient enrollment.

There was also an increase of $1.6 million in non-cash stock-based compensation expense.

There was also an increase of $1.9 million in supplies and contract research, an increase of $1.8 million in preclinical activities and contract manufacturing attributable to increases in our preclinical development activities and drug discovery research and an increase of $1.5 million in clinical costs due to ongoing clinical trial startup and patient enrollment.

Our research and development expenses increased by $33.9 million during the nine months ended August 31, 2021, compared to the nine months ended August 31, 2020.

The increase was primarily related to an increase of $11.3 million in compensation and related personnel costs attributable to an increase in headcount and an increase of $4.5 million in non-cash stock-based compensation expense.

There was also an increase of $9.4 million in supplies and contract research and an increase of $2.7 million in preclinical activities and contract manufacturing attributable to increases in our preclinical development activities and drug discovery research and an increase of $3.3 million in clinical costs due to the start of clinical trial startup and patient enrollment.

There was also an increase in facility and other costs of $2.6 million primarily due to expansion of leased premises and other costs associated with a growing company.

General and Administrative Expenses

Our general and administrative expenses increased by $4.2 million during the three months ended May 31, 2021, compared to the three months ended May 31, 2020.

The increase was primarily related to an increase of $3.0 million in compensation related expenses attributable to a higher headcount.

Our general and administrative expenses increased by $4.0 million during the three months ended August 31, 2021, compared to the three months ended August 31, 2020.

The increase was primarily related to an increase of $1.2 million in compensation related expenses attributable to a higher headcount and an increase of $1.6 million in non-cash stock-based compensation expense.

There was also an increase of $0.9 million in consultant and other professional service expenses primarily related to becoming a public company.

Our general and administrative expenses increased by $8.3 million during the six months ended May 31, 2021, compared to the six months ended May 31, 2020.

The increase was primarily related to an increase of $5.5 million in compensation related expenses attributable to a higher headcount.

Compensation and related personnel costs includes $3.4 million of non-cash stock-based compensation expense in the six months ended May 31, 2021, compared to $0.3 million in the six months ended May 31, 2020.

Our general and administrative expenses increased by $12.3 million during the nine months ended August 31, 2021, compared to the nine months ended August 31, 2020.

The increase was primarily related to an increase of $3.6 million in compensation related expenses attributable to a higher headcount and an increase of $4.7 million in non-cash stock-based compensation expense.

There was also an increase of $3.0 million in consultant and other professional service expenses primarily related to becoming a public company.

Interest and Other Income, Net

Interest and other income, net was insignificant for each of the three and six months ended May 31, 2021 and 2020 and is related to interest earned on our deposits, money market funds and investments.

Provision for Income Taxes

Provision for income taxes was $0.1 million and $0.2 million for the three and six months ended May 31, 2021.

For the three and six months ended May 31, 2020, an income tax benefit of $20.6 million was recognized related to a discrete tax benefit, which consists of carryback claims and the reversal of the uncertain tax liability related to research and development tax credits as a result of the CARES Act.

Interest and other income, net was $39 thousand and $0.5 million for the three and nine months ended August 31, 2021, respectively, and $0.7 million and $1.1 million for the three and nine months ended August 31, 2020, respectively, and is primarily related to interest earned on our deposits, money market funds and investments.

Provision (Benefit) for Income Taxes

An income tax benefit of $0.1 million and an income tax expense of $0.1 million was recognized for the three and nine months ended August 31, 2021, respectively.

No income tax was recognized during the three months ended August 31, 2020.

For the nine months ended August 31, 2020, an income tax benefit of $20.6 million was recognized related to a discrete tax benefit, which consists of carryback claims and the reversal of the uncertain tax liability related to research and development tax credits as a result of the CARES Act.

Liquidity and Capital Resources

6 unchanged sentences

We do not have any products approved for sale, and we have not generated any revenue from product sales.

As of May 31, 2021, we had $496.5 million in cash, cash equivalents and investments.

As of August 31, 2021, we had $465.4 million in cash, cash equivalents and investments.

Funding Requirements

3 unchanged sentences

Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated pre-clinical studies and clinical trials.

We have a shelf registration statement on Form S-3 on file with the SEC.

This shelf registration statement, which includes a base prospectus, allows us at any time to offer and sell registered common stock, preferred stock, debt securities, warrants, subscriptions rights and or units or any combination of securities described in the prospectus in one or more offerings.

In addition, in August 2021, we entered into an Equity Distribution Agreement with Piper Sandler & Co.

(Piper Sandler) pursuant to which, from time to time, we may offer and sell through Piper Sandler up to $150.0 million of the common stock registered under the shelf registration statement pursuant to one or more “at the market” offerings.

We are not required to sell any shares at any time during the term of the Equity Distribution Agreement.

We agreed to pay Piper Sandler a commission of 3% of the gross sales price of any shares sold pursuant to the Equity Distribution Agreement.

As of August 31, 2021, we have not sold any shares of common stock pursuant to the Equity Distribution Agreement and $150.0 million in shares remained available under the Equity Distribution Agreement.

Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, which may include funding for working capital, financing capital expenditures, research and development, clinical trials, marketing and distribution efforts, and if opportunities arise, for acquisitions or strategic alliances.

Pending such uses, we may invest the net proceeds in interest-bearing securities.

In addition, we may conduct concurrent or other financings at any time.

Our future funding requirements will depend on many factors, including the following:

the progress, costs and results of our planned Phase 1 clinical trials for our lead drug candidates NX-2127 and NX-1607 and other drug candidates, and any future clinical development of such drug candidates;

the progress, costs and results of our planned Phase 1 clinical trials for our lead drug candidates NX-2127, NX-1607, NX-5948 and DeTIL-0255 and other drug candidates, and any future clinical development of such drug candidates;

the scope, progress, costs and results of preclinical and clinical development for our other drug candidates and development programs;

11 unchanged sentences

The following table summarizes our cash flows during the periods indicated:

Six Months Ended May 31,

Nine Months Ended August 31,

(in thousands)

4 unchanged sentences

Operating activities

Net cash used in operating activities was $23.5 million for the six months ended May 31, 2021 and consisted of our net loss of $50.7 million, offset by a decrease in net assets of $18.7 million and non-cash adjustments of $8.5 million.

The decrease in net assets consisted primarily of an increase in deferred revenue of $12.4 million, a decrease in contract assets of $7.5 million due to payments received under the Gilead Agreement and an increase in accounts receivable of $2.5 million.

Net cash used in operating activities was $53.5 million for the nine months ended August 31, 2021 and consisted of our net loss of $79.5 million, offset by a decrease in net assets of $11.8 million and non-cash adjustments of $14.2 million.

The decrease in net assets consisted primarily of an increase in deferred revenue of $8.1 million, a decrease in income tax receivable of $3.6 million due to refunds received, an increase in accrued and other liabilities of $2.8 million and a decrease in contract assets of $2.5 million due to payments received under the Gilead Agreement, offset by an increase in prepaid expenses and other assets of $6.0 million primarily due to increased prepaid clinical costs.

Non-cash adjustments primarily consisted of stock-based compensation expenses of $11.0 million and depreciation and amortization expenses of $2.0 million.

Net cash provided by operating activities was $26.5 million for the six months ended May 31, 2020 and consisted of a decrease in net assets of $29.7 million and non-cash adjustments of $1.7 million, offset by our net loss of $4.8 million.

The decrease in net assets consisted primarily of an increase in deferred revenue of $51.5 million from the payment received under the Sanofi Agreement, partially offset by an increase in income tax receivable of $19.6 million related to the expected refund following the enactment of the CARES Act.

Non-cash adjustments primarily consisted of depreciation and amortization expenses of $1.0 million and stock-based compensation expense of $0.7 million.

Net cash provided by operating activities was $20.4 million for the nine months ended August 31, 2020 and consisted of a decrease in net assets of $40.3 million and non-cash adjustments of $3.4 million, offset by our net loss of $23.3 million.

The decrease in net assets consisted primarily of an increase in deferred revenue of $47.4 million, offset by an increase in prepaid expenses and other assets of $4.4 million and an increase in income tax receivable of $3.9 million.

Non-cash adjustments primarily consisted of stock-based compensation expenses of $1.8 million and depreciation and amortization expenses of $1.5 million.

Investing activities

Net cash used in investing activities was $59.5 million for the six months ended May 31, 2021 and consisted primarily of the purchase of investments of $183.2 million, partially offset by the sale of investments of $7.0 million and the maturity of investments of $119.7 million.

Net cash used in investing activities was $21.8 million for the six months ended May 31, 2020 and consisted primarily of the purchase of investments of $29.6 million, partially offset by the maturity of investments of $9.9 million.

Net cash used in investing activities was $71.7 million for the nine months ended August 31, 2021 and consisted of the purchase of investments of $257.8 million and the purchase of property and equipment of $4.8 million, offset by the sale of investments of $7.0 million and the maturity of investments of $183.9 million.

Net cash used in investing activities was $129.8 million for the nine months ended August 31, 2020 and consisted of the purchase of investments of $141.1 million and the purchase of property and equipment of $3.6 million, offset by the maturity of investments of $14.9 million.

Financing activities

Net cash provided by financing activities was $151.8 million for the six months ended May 31, 2021 and consisted primarily of proceeds from the issuance of common stock from the follow-on offering in March 2021.

Net cash provided by financing activities was $119.7 million for six months ended May 31, 2020 and consisted primarily of net proceeds from the sale of our Series D redeemable convertible preferred stock in March 2020.

Net cash provided by financing activities was $153.4 million for the nine months ended August 31, 2021 and consisted primarily of proceeds from the issuance of common stock from the follow-on offering in March 2021.

Net cash provided by financing activities was $340.2 million for the nine months ended August 31, 2020 and consisted primarily of net proceeds from the issuance of common stock related to our initial public offering in July 2020 and the sale of our Series D redeemable convertible preferred stock in March 2020.

Contractual Obligations and Other Commitments

The following table summarizes our contractual obligations as of May 31, 2021:

The following table summarizes our contractual obligations as of August 31, 2021:

Payments due by period

9 unchanged sentences

We will remain an EGC until the earliest of:

(i) the last day of the fiscal year in which we have total annual gross revenues

of $1.07 billion or more;

(i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more;

(ii) the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering;

10 unchanged sentences

and (iv) disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation.

As of November 30, 2021, we will lose our status as an EGC and will no longer be able to take advantage of the exemptions from various reporting requirements beginning with our annual report for the fiscal year ending November 30, 2021 to be filed in 2022.

We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700.0 million as of the prior May 31 and our annual revenue is less than $100.0 million during the most recently completed fiscal year.

5 unchanged sentences

generally accepted accounting principles (U.S.

The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods.

reported revenue generated and expenses incurred during the reporting periods.

Our estimates are based on our historical experience and on other relevant assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.

1 unchanged sentence

Our critical accounting policies and more significant areas involving management’s judgments and estimates used in preparation of our financial statements are discussed in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 Form 10-K.

Other than the updated policy on revenue recognition disclosed in Note 2, Summary of Significant Accounting Policies , to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, there have been no significant changes to these policies for the three and six months ended May 31, 2021.

Recent Accounting Pronouncements

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis